WELCOME TO BIOVEN
The Bioven Group's main focus is on the treatment of cancer. Bioven has a dual strategy of developing its own IP as well as in-licensing compounds to be developed through late-stage clinical trials prior to out-licensing to major healthcare or specialty pharma companies.
Meet us at the 32nd Annual JP Morgan Healthcare Conference, San Francisco, 13-16 January 2014.
To arrange a meeting, please contact email@example.com